Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The rationale for anti-tumour necrosis factor-alpha (anti-TNFalpha) therapy in rheumatoid arthritis (RA) is based on experiments on cultures of human rheumatoidjoint tissue, supported by experiments in animal models, all of which demonstrated that anti-TNFalpha antibody had profound effects on the disease activity. Clinical trials have substantiated this concept, and we have used the serum samples from the clinical trials, as well as biopsies to study the changes occurring during anti-TNFalpha therapy as clues to the pathogenesis of RA. The major effects of anti-TNFalpha therapy are in downregulating cytokine activity, and in reducing leucocyte trafficking to the joints.

Type

Journal article

Journal

International archives of allergy and immunology

Publication Date

12/1996

Volume

111

Pages

362 - 365

Addresses

Kennedy Institute of Rheumatology, Sunley Division, London, UK.

Keywords

Animals, Humans, Arthritis, Rheumatoid, Disease Models, Animal, Tumor Necrosis Factor-alpha, Antibodies, Monoclonal, Immunotherapy, Autoimmunity